Replies to post #152212 on Biotech Values

[DewDiligence]

Wall Street isn’t (yet) getting that ABT is the leader of the pack in all-oral HCV, at least for genotype-1. GILD and BMY are duking it out for the privilege of being #2, IMO.

[DewDiligence]

Here’s ABT’s PR on the phase-3 HCV program disclosed on yesterday’s webcast and discussed in #msg-81414058 and the Reply chain to that post:

http://finance.yahoo.com/news/abbott-announces-phase-3-hepatitis-180000078.html